Greffex, Inc.

24/02/2023

We have some exciting things in development here at Greffex, Inc. Take a look at our Press Release to keep up to date!

Houston, Texas, Jan. 10, 2023 - Greffex, Inc. (Greffex) and Houston Christian University (HCU) have approved an agreement to partner in the development of l ...

24/09/2021

Greffex’s Scientific Writer Katherine Durrant and her daughter team up for the 43rd Friehofer’s Run for Women again after 17 years – check out the article below!

https://www.timesunion.com/sports/article/Mother-daughter-team-returns-to-Freihofer-s-Run-16477482.php

They'll return to Albany at 9 a.m. Saturday to run in the 43rd Freihofer's Run for Women,...

20/05/2021

Position Summary:
As a member of the Greffex science team, this position will be responsible for understanding and performing testing of products or troubleshooting related projects. The purpose of this role is to provide technical and analytical assistance in development of viral based vaccines and gene therapy delivery systems.

Examples of Duties and Responsibilities:
The duties and responsibilities may include, but are not limited to the following:
• Conduct experiments in DNA/oligo quantification, gene amplification, sequencing, and other relevant experiments in molecular biology or related fields.
• Passaging of immortalized human cell lines, both in suspension and adherent, using aseptic techniques.
• Work safely and comfortably under BSL2 conditions.
• Protein purification
• Comply with all quality policies and actively participate in maintenance and updating of all required SOP’s and quality records of equipment maintenance, tests, analyses and designing experiments as needed.
• Manage and prioritize daily assignments approved by Supervisor to ensure completion of the assignment.
• Manage and maintain required reagents, laboratory environment and equipment needed to carry out assignments.
• Collaborate closely with other teams in the department to complete highest priority work as directed.
• Responsible for understanding and implementing relevant company and department policies and procedures.
• Attendance and participation in schedules planning meetings and/or status meetings.

Education/Training Experience:
• Bachelor’s degree in the Biological Sciences or related fields.
• Courses and bench experience in genomic studies recommended.
• Basic course work in molecular biology, nucleic acid chemistry or equivalent.
• Fluorescent microscope and FPLC chromatography experience recommended, but not required.
• Must be highly motivated individual that can work with with minimal supervision.

Please contact Janae at jcull@greffex.com with resume and questions.

20/05/2021

Position Summary:
We are looking for a new administrative assistant to support both our executive and science teams. This position would manage mostly business-related tasks such as creating reports, taking meeting minutes, reviewing bookkeeping and other organizational tasks. This position will also be responsible for basic accounting tasks, preparing financial reports, filing and organization.

Examples of Duties and Responsibilities:
The duties and responsibilities include, but are not limited to the following:
• Maintaining files and updated records.
• Attendance and participation in schedule planning meetings and/or status meetings.
• Handling basic bookkeeping skills.
• Track orders and supplies.
• Reviewing, filing and retrieving corporate accounting records, documents and reports.
• Accurately record minutes from meetings.
• Using various software, including word processing, spreadsheets, databases, and presentation software.
• Provide general administrative support.

Education/Training Experience:
• High school diploma or equivalent.
• Must have excellent communication and organizing skills.
• Must be a highly motivated individual with minimal supervision.
• Must be able to meet deadlines in a fast-paced quickly changing environment.
• Must have a proactive approach to problem-solving with strong decision-making skills.
• Professional level verbal and written communications skills.

Please reply to this posting or contact Janae at jcull@greffex.com with resume and questions.

11/08/2020

06/07/2020

Our recent partnership with Fujifilm Diosynth Biotechnologies is a crucial step toward the manufacturing of GreVac® products on a global scale. Greffex looks forward to working with such an accomplished CDMO as we continue to engineer safe and effective gene delivery products using our Universal Vector Platform.

HOUSTON (PRWEB) June 08, 2020 -- Greffex, a leading genetic engineering company announced a key manufacturing agreement with FUJIFILM Diosynth Biotechnologies to produce its vaccine in the United States.

04/10/2019

Greffex is excited to announce that we have been awarded an NIH contract for up to $18.9 Million to develop a Plug-And-Play Technology for vaccine development. Read the full release here: https://www.greffex.com/greffex-awarded-nih-contract/

Greffex, Inc. Awarded NIH Contract for up to $18.9 Million to Develop a Plug-And-Play Technology Platform to Expedite the Production of Vaccine Candidates for Biodefense and Emerging Infectious Diseases. October 4, 2019October 4, 2019 admin View the full press release hereDownload HOUSTON, TX., Sept...

06/12/2017

Greffex, Inc., a company leading a paradigm shift in the design, development and production of vaccines, elected two new members to its board of directors on Monday. They are John D. White, founder and chairman of PSP Capital and former U.S. Ambassador to Qatar, Chase Untermeyer. Both are accomplished leaders and will bring significant global and national experience to Greffex, Inc.

“John and Chase are both strong leaders with impressive accomplishments and contributions that span across business and public service,” said John R. Price, Co-Chairman of the Board, President and Chief Executive of Greffex, Inc. “They will serve as valuable additions to the board.”

Read the full press release on our website

Greffex, Inc. elects two new board members Greffex, Inc., a company leading a paradigm shift in the design, development and production of vaccines, elected two new members to its board of directors on Monday. They are John D. White, founder and chairman of PSP Capital and former U.S. Ambassador to Q...

15/05/2017

We are excited to announce that Greffex Inc. and the Texas A&M University System (TAMUS) are collaborating through a Masters Research Agreement to establish an efficient pipeline of countermeasures to biological threats in the US and worldwide.

Texas A&M University System (TAMUS) and Greffex, Inc. Sign Agreement to collaborate on advanced process and manufacturing development.

10/05/2016

Greffex has a Zika vaccine ready for testing! The vaccine is based on the GreVac© platform also employed for current MERS Co-V and Avian Flu vaccine candidates.

Read a paper from CEO John R. Price on the potential for a Zika vaccine, as well as a summary of the companies currently working toward that goal.

Zika Vaccine Greffex has a Zika vaccine ready for testing Read the full response from Greffex CEO John R. Price here, including a summary of potential vaccines from companies around the world: CEO John R. Price- Zika write-up The Zika virus, transmitted by mosquitos, is garnering more and more atten...

24/02/2016

Adenovirus-based vaccines have largely relied on well-established cell production techniques for large scale applications, and techniques continue to be honed as more vaccines go into clinical trials. Greffex has experimented with several methods and continues to refine them in order to find the most cost-effective way to produce vaccines on a global scale.

Biotechnol J. 2015 May;10(5):741-7. doi: 10.1002/biot.201400390. Epub 2015 Apr 24. Research Support, Non-U.S. Gov't; Review

12/02/2016

Greffex is currently developing a vaccine for the Zika virus and hopes to get it into trials as soon as possible.

This article from the International Business Times outlines many issues faced by smaller biotechnology companies and vaccine development in general (featuring a quote from CEO John Price).

If the process of developing a vaccine were different, could scientists produce more effective inoculations in less time?

18/11/2015

Unlike antibiotics, our GREVAX™ Universal Platform fights disease by targeting the human immune system toward specific infections with no risk of .

14/08/2015

The Greffex MERS vaccine was able to establish immune response in 100% of mice, but we are still working to fund further trials. (via Global Health Technologies Coalition)

Since its discovery in 2012, cases of Middle East Respiratory Syndrome (MERS)—a disease World Health Organization (WHO) Director-General Dr. Margaret Chan called “a threat to the entire world”— hav...

18/06/2015

In light of the recent MERS outbreak in South Korea and the H5N1 outbreak amongst US poultry populations, Greffex reaffirms its commitment to creating effective vaccines. We are currently working with government agencies to secure funding to further our MERS and H5N1 vaccine candidates.

IN A BID to control the spread of the Middle East Respiratory Syndrome coronavirus (MERS-CoV) in South Korea, the World Health Organization (WHO) has recommended to all of its members to continue their surveillance for acute respiratory infections and to carefully review any unusual patterns, especi…

10/06/2015

"Greffex reached another milestone in its quest to increase manufacturing efficiencies and reduce costs of its GreVAX vaccines," says CEO John R. Price. Greffex scientists led by Dr. Staerz were able to further enhance production recovery of its highly immunogenic MERS-CoV candidate vaccine by more than 10-fold, insuring the lowest cost of production.

09/06/2015

Greffex was just featured in the International Business Times for our MERS vaccine candidate:

Several vaccines and treatments for MERS are in development, but none have completed clinical trials.

04/06/2015

Greffex has developed a MERS vaccine candidate that is now being tested. If the new cases in South Korea and China reveal any mutations in the virus, Greffex can develop an updated MERS vaccine within three weeks. For more information on our MERS vaccine candidate, visit www.greffex.com/vaccines/mers

WHO warns that the MERS outbreak in South Korea is likely to grow, as 1,364 people remain under quarantine and confirmed cases grew to 30 people.